Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity C-reactive protein, despite ...

About 1 in 3 people with psoriasis who achieved clear skin with biologic drugs still had underlying inflammation that may ...

A retrospective analysis of US medical records of people aged 65-95 years finds those with psoriasis on systemic therapies ...

SAN DIEGO — Disease-modifying antirheumatic drugs (DMARDs) and biologics were linked to as much as a 74.5% reduction in the risk for alopecia areata (AA) in patients with psoriasis, a new ...

The researchers found that 36.3% of patients had residual inflammation. (HealthDay News) — For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as ...

WEDNESDAY, May 21, 2025 (HealthDay News) -- For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by ...

Discover a study in which researchers examined three international cohorts of patients with moderate-to-severe psoriasis ...

Adults with plaque psoriasis aged 65 years and older had similar responses to IL-17 and IL-23 inhibitors to that of younger adults.

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and ...

They’re typically prescribed if you have moderate to severe psoriasis or your symptoms no longer respond to topical treatments. Biologics: Biologics are a type of DMARD made from living cells ...